FDA Clarifies Orphan Designation for Pediatric Subpopulations of Common Diseases

Summary

The FDA has released a final guidance to resolve an unintended loophole in the Pediatric Research Equity Act (PREA) orphan exemption process, stating that it will not grant additional orphan-drug designations for pediatric subpopulations of common diseases with a prevalence of 200,000 or greater.